118 related articles for article (PubMed ID: 15251568)
1. Thyroid hormone excess and bone--a clinical review.
Cobin RH
Endocr Pract; 1995; 1(6):404-9. PubMed ID: 15251568
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.
Garton M; Reid I; Loveridge N; Robins S; Murchison L; Beckett G; Reid D
Clin Endocrinol (Oxf); 1994 Dec; 41(6):747-55. PubMed ID: 7889610
[TBL] [Abstract][Full Text] [Related]
3. Long-term thyroxine treatment and bone mineral density.
Franklyn JA; Betteridge J; Daykin J; Holder R; Oates GD; Parle JV; Lilley J; Heath DA; Sheppard MC
Lancet; 1992 Jul; 340(8810):9-13. PubMed ID: 1351654
[TBL] [Abstract][Full Text] [Related]
4. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Schneider DL; Barrett-Connor EL; Morton DJ
JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
[TBL] [Abstract][Full Text] [Related]
6. Effect of replacement doses of thyroxine on bone mineral density.
Hanna FW; Pettit RJ; Ammari F; Evans WD; Sandeman D; Lazarus JH
Clin Endocrinol (Oxf); 1998 Feb; 48(2):229-34. PubMed ID: 9579237
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
Franklyn J; Betteridge J; Holder R; Daykin J; Lilley J; Sheppard M
Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
[TBL] [Abstract][Full Text] [Related]
8. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
9. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
12. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
13. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
14. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in postmenopausal women treated with L-thyroxine.
Adlin EV; Maurer AH; Marks AD; Channick BJ
Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
18. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
[TBL] [Abstract][Full Text] [Related]
19. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
20. High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.
Hwangbo Y; Kim JH; Kim SW; Park YJ; Park DJ; Kim SY; Shin CS; Cho NH
Osteoporos Int; 2016 Feb; 27(2):457-62. PubMed ID: 26252978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]